These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20100855)

  • 21. A C-terminal domain targets the Pseudomonas aeruginosa cytotoxin ExoU to the plasma membrane of host cells.
    Rabin SD; Veesenmeyer JL; Bieging KT; Hauser AR
    Infect Immun; 2006 May; 74(5):2552-61. PubMed ID: 16622190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detrimental Effect of Type I IFNs During Acute Lung Infection With
    Pylaeva E; Bordbari S; Spyra I; Decker AS; Häussler S; Vybornov V; Lang S; Jablonska J
    Front Immunol; 2019; 10():2190. PubMed ID: 31572395
    [No Abstract]   [Full Text] [Related]  

  • 23. ExoU Induces Lung Endothelial Cell Damage and Activates Pro-Inflammatory Caspase-1 during
    Hardy KS; Tuckey AN; Renema P; Patel M; Al-Mehdi AB; Spadafora D; Schlumpf CA; Barrington RA; Alexeyev MF; Stevens T; Pittet JF; Wagener BM; Simmons JD; Alvarez DF; Audia JP
    Toxins (Basel); 2022 Feb; 14(2):. PubMed ID: 35202178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute exposure to silica nanoparticles enhances mortality and increases lung permeability in a mouse model of Pseudomonas aeruginosa pneumonia.
    Delaval M; Boland S; Solhonne B; Nicola MA; Mornet S; Baeza-Squiban A; Sallenave JM; Garcia-Verdugo I
    Part Fibre Toxicol; 2015 Jan; 12(1):1. PubMed ID: 25605549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphatidylinositol 4,5-bisphosphate is a novel coactivator of the Pseudomonas aeruginosa cytotoxin ExoU.
    Tyson GH; Hauser AR
    Infect Immun; 2013 Aug; 81(8):2873-81. PubMed ID: 23716613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pseudomonas aeruginosa ExoU augments neutrophil transepithelial migration.
    Pazos MA; Lanter BB; Yonker LM; Eaton AD; Pirzai W; Gronert K; Bonventre JV; Hurley BP
    PLoS Pathog; 2017 Aug; 13(8):e1006548. PubMed ID: 28771621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudomonas aeruginosa ExoU, a toxin transported by the type III secretion system, kills Saccharomyces cerevisiae.
    Rabin SD; Hauser AR
    Infect Immun; 2003 Jul; 71(7):4144-50. PubMed ID: 12819106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effector ExoU from the type III secretion system is an important modulator of gene expression in lung epithelial cells in response to Pseudomonas aeruginosa infection.
    McMorran B; Town L; Costelloe E; Palmer J; Engel J; Hume D; Wainwright B
    Infect Immun; 2003 Oct; 71(10):6035-44. PubMed ID: 14500525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A live auxotrophic vaccine confers mucosal immunity and protection against lethal pneumonia caused by Pseudomonas aeruginosa.
    Cabral MP; Correia A; Vilanova M; Gärtner F; Moscoso M; García P; Vallejo JA; Pérez A; Francisco-Tomé M; Fuentes-Valverde V; Bou G
    PLoS Pathog; 2020 Feb; 16(2):e1008311. PubMed ID: 32040500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prevalence of cytotoxicity effectors in nosocomial Pseudomonas Aeruginosa strains].
    Kuznetsova MV; Maksimova AV; Karpunina TI; Demakov VA
    Zh Mikrobiol Epidemiol Immunobiol; 2014; (6):9-14. PubMed ID: 25816507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ExoU-induced vascular hyperpermeability and platelet activation in the course of experimental Pseudomonas aeruginosa pneumosepsis.
    Machado GB; de Assis MC; Leão R; Saliba AM; Silva MC; Suassuna JH; de Oliveira AV; Plotkowski MC
    Shock; 2010 Mar; 33(3):315-21. PubMed ID: 19543153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
    Hauser AR; Cobb E; Bodi M; Mariscal D; Vallés J; Engel JN; Rello J
    Crit Care Med; 2002 Mar; 30(3):521-8. PubMed ID: 11990909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia.
    Mueller-Ortiz SL; Drouin SM; Wetsel RA
    Infect Immun; 2004 May; 72(5):2899-906. PubMed ID: 15102802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury.
    Finck-Barbançon V; Goranson J; Zhu L; Sawa T; Wiener-Kronish JP; Fleiszig SM; Wu C; Mende-Mueller L; Frank DW
    Mol Microbiol; 1997 Aug; 25(3):547-57. PubMed ID: 9302017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphatidylinositol 4,5-Bisphosphate-Dependent Oligomerization of the Pseudomonas aeruginosa Cytotoxin ExoU.
    Zhang A; Veesenmeyer JL; Hauser AR
    Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils.
    Dacheux D; Toussaint B; Richard M; Brochier G; Croize J; Attree I
    Infect Immun; 2000 May; 68(5):2916-24. PubMed ID: 10768989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lysophospholipase A activity of Pseudomonas aeruginosa type III secretory toxin ExoU.
    Tamura M; Ajayi T; Allmond LR; Moriyama K; Wiener-Kronish JP; Sawa T
    Biochem Biophys Res Commun; 2004 Apr; 316(2):323-31. PubMed ID: 15020221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa.
    Wong-Beringer A; Wiener-Kronish J; Lynch S; Flanagan J
    Clin Microbiol Infect; 2008 Apr; 14(4):330-6. PubMed ID: 18190571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of loop-mediated isothermal amplification assays for genotyping of Type III Secretion System in Pseudomonas aeruginosa.
    Shi H; Chen Z; Kan J
    Lett Appl Microbiol; 2015 Oct; 61(4):361-6. PubMed ID: 26219625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense.
    Steinhauser ML; Hogaboam CM; Kunkel SL; Lukacs NW; Strieter RM; Standiford TJ
    J Immunol; 1999 Jan; 162(1):392-9. PubMed ID: 9886412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.